Scientists identify new way of attacking breast cancer

April 18, 2017
Credit: University of Manchester

Scientists have discovered a brand new way of attacking breast cancer that could lead to a new generation of drugs.

Researchers have revealed a new driver for the growth and spread of cells and have designed a novel type of to block it.

The next step will be to select the most effective drug from this new class of inhibitors and take it into clinical trials of patients.

A team at The Institute of Cancer Research, London working with a team at the Cancer Research UK Manchester Institute at The University of Manchester discovered that a protein called lysyl oxidase, or LOX, plays an important role in driving growth and cancer spread (metastasis).

The researchers found, in mice, that LOX seemed to help breast 'trap' growth receptors on their surface as a means of growing more quickly.

Crucially, the team also designed and validated a prototype drug, called CCT365623, which blocks this function, and is able to slow tumour growth and metastases in mice.

The study is published in Nature Communications today (Tuesday) and was funded by Wellcome, Cancer Research UK, and The Institute of Cancer Research (ICR).

Previously, LOX had been known for its ability to help control formation of the extracellular matrix that holds tissues together, and its use by cancer cells to travel more easily around the body.

But this major new study reveals for the first time how LOX is able to control tumour growth. The team discovered that the strongest effect of LOX depletion in was a reduction in the surface levels of epidermal growth factor receptor (EGFR), a receptor which is often responsible for promoting cancer growth.

Scientists worked with mice that spontaneously develop breast cancer and demonstrated that they could reduce both the tumour volume and the size and number of metastases when they genetically removed the LOX gene. All the mice that had the LOX gene genetically removed from their cancer cells survived more than 50 days.

The teams also created CCT365623, a new inhibitor of LOX. In mice that had developed breast cancer, the drug slowed and reduced cancer spread with no side-effects.

LOX has also been shown to be involved in bowel, prostate, pancreatic and lung cancer, so treatments targeting it could potentially benefit a wide range of patients.

Professor Caroline Springer, joint senior author and Team Leader of Gene and Oncogene Targeting at The Institute of Cancer Research, London, said:

"We knew that LOX had a role in cancer's spread round the body, but to discover how it also appears to drive the growth of breast cancer cells is a real game changer. It means that drugs that disrupt LOX's ability to promote growth signals might be able to slow or block cancer progression in patients – as we saw in mice."

Professor Richard Marais, joint senior author and Director of the Cancer Research UK Manchester Institute at The University of Manchester, said:

"In this study we show how improving our knowledge of cancer biology can spearhead the development of new drugs. By understanding better how LOX works, we will make new precision drugs that could improve the survival of patients with many different types of cancer."

Dr Justine Alford, senior science information officer at Cancer Research UK, said:

"This research in mice is exciting because it not only reveals new details of how breast cancer grows and spreads, but it could lead to a completely new way to stop these processes in patients if proven in people. This could help improve outcomes for patients, since cancer that has spread is harder to treat. LOX is also thought to play a role in a number of other cancers, so this research could also have applications beyond breast cancer."

Explore further: Looking beyond cancer cells to understand what makes breast cancer spread

More information: HaoRan Tang et al. Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface, Nature Communications (2017). DOI: 10.1038/ncomms14909

Related Stories

Immune system plays dual role in breast cancer

February 8, 2017

The immune system plays a paradoxical role in the spread of breast cancer. Some immune cells contribute to metastasis, while other cells can be activated to strengthen the effect of chemotherapy. Kelly Kersten made this discovery ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Savior of T-cells may be enemy of liver immune cells

April 24, 2017

Researchers at Houston Methodist demonstrated that a surface protein called OX40, responsible for keeping one type of immune system cell alive, can trigger the death of liver immune cells, in turn starting a chain reaction ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Sunshine29
not rated yet Apr 18, 2017
VuVa Magnetic Dilators are a safe alternative that helps with painful intercourse after breast cancer treatment.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.